Dual-mode MRI nanoprobe mimics biological processes to pinpoint early fibrosis in fatty liver disease

Dual-mode MRI nanoprobe mimics biological processes to pinpoint early fibrosis in fatty liver disease

A research team has developed an innovative biomimetic dual-mode magnetic resonance imaging (MRI) nanoprobe for detecting early-stage liver fibrosis in non-alcoholic fatty liver disease (NAFLD).

AI-CVD™ opportunistic detection of fatty liver in coronary calcium scans predicts cardiovascular events and mortality

HOUSTON, TX, UNITED STATES, April 22, 2025 /EINPresswire.com/ -- Naghavi M, Atlas K, Reeves A, Zhang C, Wasserthal J, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Budoff MJ, Branch AD, Ma N, Yip R, Fan W, Roy SK, Nasir K, Molloi S, Fayad Z, McConnell MV, Kakadiaris I, Maron DJ, Narula J, Williams K, Shah PK, Abela G, Vliegenthart R, Levy D, Wong ND. AI-enabled opportunistic measurement of liver steatosis in coronary artery calcium scans pre…

Drug Candidate Successfully Treats Atherosclerosis, Fatty Liver Disease in Large Mammals

A drug candidate previously successful at treating severe fatty liver disease, reduces atherosclerosis in large mammals, a study suggests. The compound, DT-109, presents as a dual-action drug capable of treating both metabolic dysfunction-associated steatotic liver disease (MASH) and the vascular complications associated with atherosclerosis, a significant advancement in the treatment landscape.

MicroRNA-26b protects against MASH development in mice and can be efficiently targeted with lipid nanoparticles

The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) is increasing, urging more research into the underlying mechanisms. MicroRNA-26b (Mir26b) might play a role in several MASH-related pathways. Therefore, we aimed to determine the role of Mir26b in MASH and its therapeutic potential using Mir26b mimic-loaded lipid nanoparticles (LNPs). Apoe-/-Mir26b-/-, Apoe-/-Lyz2creMir26bfl/fl mice, and respective controls were fed a West…